Selegiline in the treatment of Parkinson's disease: Its impact on orthostatic hypotension

Parkinsonism and Related Disorders

Volumn 9, Issue 4, 2003, Pages 221-224

  Bhattacharya, K F ^a,b   Nouri, S ^a   Olanow, C W ^a   Yahr, M D ^a   Kaufmann, H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Autonomic nervous system; Blood pressure; Parkinson's disease; Selegiline

Indexed keywords

CARBIDOPA; LEVODOPA; SELEGILINE;

ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CARDIOVASCULAR REFLEX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEART RATE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; REFLEX; STANDING;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CARBIDOPA; DRUG THERAPY, COMBINATION; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPOTENSION, ORTHOSTATIC; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SELEGILINE; SUPINE POSITION;

EID: 0037334475     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(02)00053-6     Document Type: Article

References (45)

1. Myllyla V.V., Sotaniemi K.A., Vuorinen J.A., Heinonen E.H. Selegiline as a primary treatment of Parkinson's disease. Acta Neurol Scand Suppl. 136:1991;70-72.
2. Koller W.C. Selegiline monotherapy in the treatment of Parkinson's disease. Neurology. 47:(Suppl. 3):1996;S196-S199.
3. Brannan T., Yahr M.D. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol. 37:(1):1995;95-98.
4. Myllyla V.V., Sotaniemi K., Maki-Ikola O., Rinne U.K., Heinonen E.H. Role of selegiline in combination therapy of Parkinson's disease. Neurology. 47:(Suppl. 3):1996;S200-S209.
5. Lees A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom (see comments). Br Med J. 311:(7020):1995;1602-1607.
6. Ben-Shlomo Y., Churchyard A., Head J., Hurwitz B., Overstall P., Ockelford J., et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. Br Med J. 316:(7139):1998;1191-1196.
7. Montastruc J.L., Chaumerliac C., Desboeuf K., Manika M., Bagheri H., Rascol O., et al. Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin Neuropharmacol. 23:(5):2000;271-275.
8. Lyytinen J., Kaakkola S., Ahtila S., Tuomainen P., Teravainen H. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. Mov Disord. 12:(4):1997;497-505.
9. Masaki K.H., Schatz I.J., Burchfiel C.M., Sharp D.S., Chiu D., Foley D., et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation. 98:(21):1998;2290-2295.
10. Turkka J.T., Souminen K., Tolonen U., et al. Selegiline diminishes autonomic responses in Parkinson's disease. Neurology. 48:1987;662-667.
11. Churchyard A., Mathias C.J., Boonkongchuen P., Lees A.J. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease (see comments). J Neurol Neurosurg Psychiatry. 63:(2):1997;228-234.
12. Churchyard A., Mathias C.J., Lees A.J. Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal. Mov Disord. 14:(2):1999;246-251.
13. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases (see comments). J Neurol Neurosurg Psychiatry. 55:(3):1992;181-184.
14. McLeod J.G., Tuck R.R. Disorders of the autonomic nervous system: part 1. Pathophysiology and clinical features. Ann Neurol. 21:(5):1987;419-430.
15. Kaufmann H. Investigation of autonomic cardiovascular dysfunction. Korczyn A.D. Handbook of autonomic nervous system dysfunction. 1995;427-468 Marcel Dekker, New York.
16. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328(3):176-83.
17. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol. 46:(10):1989;1052-1060.
18. Haapaniemi T.H., Kallio M.A., Korpelainen J.T., Suominen K., Tolonen U., Sotaniemi K.A., et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease. J Neurol. 247:(11):2000;868-874.
19. Birkmayer W., Riederer P., Ambrozi L., Youdim M.B. Implications of combined treatment with 'Madopar' and L-deprenyl in Parkinson's disease. A long-term study. Lancet. 1:(8009):1977;439-443.
20. Lees A.J., Shaw K.M., Kohout L.J., Stern G.M., Elsworth J.D., Sandler M., et al. Deprenyl in Parkinson's disease. Lancet. 2:(8042):1977;791-795.
21. Giovannini P., Martignoni E., Piccolo I., Pacchetti C., Grassi M.P., Nappi G., et al. Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages. J Neural Transm Suppl. 22:1986;235-246.
22. Cotzias G.C., Papavasiliou P.S., Gellene R. Modification of Parkinsonism - chronic treatment with L-dopa. N Engl J Med. 280:(7):1969;337-345.
23. Godwin-Austen R.B., Tomlinson E.B., Frears C.C., Kok H.W. Effects of L-dopa in Parkinson's disease. Lancet. 2:(7613):1969;165-168.
24. Yahr M.D., Duvoisin R.C., Schear M.J., Barrett R.E., Hoehn M.M. Treatment of parkinsonism with levodopa. Arch Neurol. 21:(4):1969;343-354.
25. McDowell F.H., Lee J.E. Levodopa, Parkinson's disease, and hypotension. Ann Intern Med. 72:(5):1970;751-752.
26. Sachs C., Berglund B., Kaijser L. Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition. Acta Neurol Scand. 71:(1):1985;37-42.
27. Iwasaki S., Hamaguchi K., Iwasaki A., Takakusagi M., Narabayashi Y. Hypotensive effect of long-term levodopa in patients with Parkinson's disease. Eur Neurol. 30:(4):1990;194-199.
28. Camerlingo M., Ferraro B., Gazzaniga G.C., Casto L., Cesana B.M., Mamoli A. Cardiovascular reflexes in Parkinson's disease: long-term effects of levodopa treatment on de novo patients. Acta Neurol Scand. 81:(4):1990;346-348.
29. Goetz C.G., Lutge W., Tanner C.M. Autonomic dysfunction in Parkinson's disease. Neurology. 36:(1):1986;73-75. Issn: 0028-3878.
30. Calne D.B., Karoum F., Ruthven C.R., Sandler M. The metabolism of orally administered L-Dopa in Parkinsonism. Br J Pharmacol. 37:(1):1969;57-68.
31. Elbe J. A propsed mechanism for the depressor effect of dopamine in the anesthetized dog. J Pharmacol Exp Therapeut. 145:1964;64-70.
32. Holmes J.C.F.N. Direct effects of dopamine. Circ Res. 10:1962;68-72.
33. Farmer J.B. Indirect sympathomimetic actions of dopamine. J Pharm Pharmacol. 18:(4):1966;261-262.
34. Henning M., Rubenson A. Central hypotensive effect of L-3,4-dihydroxyphenylalanine in the rat. J Pharm Pharmacol. 22:(8):1970;553-560.
35. Watanabe A.M., Chase T.N., Cardon P.V. Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther. 11:(5):1970;740-746.
36. Watanabe A.M., Parks L.C., Kopin I.J. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors. J Clin Invest. 50:(6):1971;1322-1328.
37. Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J Neural Transm. 43:(3-4):1978;177-198.
38. Wiener H.L., Hashim A., Lajtha A., Sershen H. Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier. Eur J Pharmacol. 163:(1):1989;191-194.
39. Gerlach M., Youdim M.B., Riederer P. Pharmacology of selegiline. Neurology. 47:(Suppl. 3):1996;S137-S145.
40. Berthelsen S., Pettinger W.A. A functional basis for classification of alpha-adrenergic receptors. Life Sci. 21:(5):1977;595-606.
41. Knoll J., Ecsery Z., Magyar K., Satory E. Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action. Biochem Pharmacol. 27:(13):1978;1739-1747.
42. Glover V., Sandler M. Clinical chemistry of monoamine oxidase. Cell Biochem Funct. 4:(2):1986;89-97.
43. Reynolds G.P., Elsworth J.D., Blau K., Sandler M., Lees A.J., Stern G.M. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol. 6:(6):1978;542-544.
44. Knoll. Analysis of the pharmacological effects of the selective monoamine oxidase inhibitors. Wolstenholme G.E.W.K.J. Monoamine oxidase and its inhibition. 1976;135-161 Elsevier, Amsterdam.
45. Innes I.R. Norepinephrine, epinephrine and symapthomimetic amines. Goodman L.S. The pharmacological basis of therapeutics. 1977;477-513 MacMillan, New York.